# Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma

> **NCT06801730** · PHASE2 · RECRUITING · sponsor: **Zhifeng Tian,MD** · enrollment: 38 (estimated)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Irinotecan liposome combined with bevacizumab

## Key facts

- **NCT ID:** NCT06801730
- **Lead sponsor:** Zhifeng Tian,MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2026-12-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06801730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06801730, "Irinotecan Liposomes Combined With Bevacizumab in the Treatment of Recurrent Glioma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06801730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*